Prognostic factors in a univariate analysis of diffuse large B-cell lymphoma
| Factor . | No. of patients . | 5-year survival (%) . | Relative risk (95% CI) . | P value . | 5-year PFS (%) . | Relative risk (95% CI) . | P value . | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wilcoxon test . | Log-rank test . | Wilcoxon test . | Log-rank test . | |||||||||||||||
| International Prognostic Index | ||||||||||||||||||
| L + L-I | 192 | 85.9 | 7.18 | .0001 | .0001 | 80.1 | 3.77 | .0001 | .0001 | |||||||||
| H-I + H | 122 | 39.2 | (4.39-11.77) | 52.2 | (2.36-6.01) | |||||||||||||
| WHO performance status | ||||||||||||||||||
| 0-1 | 237 | 80.5 | 4.58 | .0001 | .0001 | 75.8 | 2.84 | .0001 | .0001 | |||||||||
| 2-4 | 77 | 35.5 | (3.01-6.99) | 50.4 | (1.78-4.53) | |||||||||||||
| Serum LDH level | ||||||||||||||||||
| Normal | 117 | 89.5 | 5.00 | .0001 | .0001 | 82.0 | 2.90 | .0001 | .0001 | |||||||||
| Above normal | 197 | 53.1 | (2.71-9.24) | 63.4 | (1.66-5.05) | |||||||||||||
| Ann Arbor stage | ||||||||||||||||||
| I, II | 139 | 81.0 | 3.05 | .0001 | .0001 | 82.8 | 2.87 | .0001 | .0001 | |||||||||
| III, IV | 175 | 57.3 | (1.86-4.99) | 59.3 | (1.70-4.83) | |||||||||||||
| Extranodal sites | ||||||||||||||||||
| 0-1 | 280 | 72.1 | 3.74 | .0001 | .0001 | 72.6 | 2.92 | .0001 | .0002 | |||||||||
| > 1 | 34 | 35.8 | (2.28-6.12) | 48.3 | (1.63-5.22) | |||||||||||||
| B symptoms | ||||||||||||||||||
| Absent | 231 | 74.2 | 2.25 | .0002 | .0001 | 73.4 | 1.83 | .0072 | .0120 | |||||||||
| Present | 83 | 51.1 | (1.47-3.46) | 61.5 | (1.13-2.94) | |||||||||||||
| Bulky disease | ||||||||||||||||||
| Absent | 266 | 70.3 | 1.30 | .5777 | .3522 | 72.0 | 1.41 | .5623 | .2404 | |||||||||
| Present | 46 | 56.5 | (0.74-2.26) | 56.8 | (0.79-2.52) | |||||||||||||
| Age at diagnosis (yr) | ||||||||||||||||||
| < 60 | 124 | 83.5 | 3.18 | .0001 | .0001 | 83.0 | 2.46 | .0008 | .0006 | |||||||||
| ≥ 60 | 190 | 57.9 | (1.87-5.40) | 61.2 | (1.44-4.17) | |||||||||||||
| Sex | ||||||||||||||||||
| Male | 164 | 69.2 | 1.06 | .7366 | .7913 | 69.6 | 1.00 | .9428 | .9940 | |||||||||
| Female | 150 | 63.7 | (0.70-1.61) | 71.5 | (0.64-1.58) | |||||||||||||
| nm23-H1 level (ng/mL) | ||||||||||||||||||
| Control + 2SD ≤ 12.01 | 127 | 83.6 | 3.87 | .0001 | .0001 | 79.5 | 2.72 | .0001 | .0001 | |||||||||
| Control + 2SD > 12.01 | 187 | 58.7 | (2.24-6.68) | 64.8 | (1.60-4.63) | |||||||||||||
| Median ≤ 17.00 | 158 | 83.2 | 4.33 | .0001 | .0001 | 80.4 | 3.32 | .0001 | .0001 | |||||||||
| Median > 17.00 | 156 | 53.9 | (2.62-7.16) | 60.3 | (2.00-5.49) | |||||||||||||
| point ≤ 32.50 | 209 | 81.6 | 5.22 | .0001 | .0001 | 79.5 | 4.11 | .0001 | .0001 | |||||||||
| point > 32.50 | 105 | 42.0 | (3.35-8.13) | 50.8 | (2.59-6.52) | |||||||||||||
| ¾ point ≤ 45.00 | 236 | 81.0 | 7.02 | .0001 | .0001 | 79.7 | 6.06 | .0001 | .0001 | |||||||||
| ¾ point > 45.00 | 78 | 53.9 | (4.55-10.83) | 37.7 | (3.83-9.60) | |||||||||||||
| ≤ 80.00 | 272 | 77.9 | 12.12 | .0001 | .0001 | 77.8 | 14.34 | .0001 | .0001 | |||||||||
| > 80.00 | 42 | 5.5 | (7.73-18.99) | 7.9 | (8.73-23.58) | |||||||||||||
| sIL-2 receptor level (U/mL) ≤ 1000 | 137 | 86.7 | 4.45 | .0001 | .0001 | 85.4 | 3.34 | .0001 | .0001 | |||||||||
| > 1000 | 177 | 53.4 | (2.58-7.66) | 57.5 | (1.96) | |||||||||||||
| sCD44 level (ng/mL) | ||||||||||||||||||
| Median ≤ 464.0 | 111 | 77.4 | 1.82 | .0248 | .0247 | 77.4 | 1.68 | .0557 | .0688 | |||||||||
| Median > 464.0 | 110 | 58.8 | (1.07-3.09) | 63.3 | (0.98-2.89) | |||||||||||||
| Control + 2SD ≤ 598.8 | 141 | 76.3 | 1.86 | .0291 | .0174 | 74.0 | 1.68 | .0401 | .0528 | |||||||||
| Control + 2SD > 598.8 | 80 | 53.6 | (1.11-3.11) | 63.5 | (0.99-2.66) | |||||||||||||
| ≤ 500 | 120 | 78.3 | 2.03 | .0093 | .0071 | 78.3 | 1.89 | .0243 | .0177 | |||||||||
| > 500 | 101 | 55.8 | (1.20-3.43) | 60.8 | (1.11-3.23) | |||||||||||||
| Factor . | No. of patients . | 5-year survival (%) . | Relative risk (95% CI) . | P value . | 5-year PFS (%) . | Relative risk (95% CI) . | P value . | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wilcoxon test . | Log-rank test . | Wilcoxon test . | Log-rank test . | |||||||||||||||
| International Prognostic Index | ||||||||||||||||||
| L + L-I | 192 | 85.9 | 7.18 | .0001 | .0001 | 80.1 | 3.77 | .0001 | .0001 | |||||||||
| H-I + H | 122 | 39.2 | (4.39-11.77) | 52.2 | (2.36-6.01) | |||||||||||||
| WHO performance status | ||||||||||||||||||
| 0-1 | 237 | 80.5 | 4.58 | .0001 | .0001 | 75.8 | 2.84 | .0001 | .0001 | |||||||||
| 2-4 | 77 | 35.5 | (3.01-6.99) | 50.4 | (1.78-4.53) | |||||||||||||
| Serum LDH level | ||||||||||||||||||
| Normal | 117 | 89.5 | 5.00 | .0001 | .0001 | 82.0 | 2.90 | .0001 | .0001 | |||||||||
| Above normal | 197 | 53.1 | (2.71-9.24) | 63.4 | (1.66-5.05) | |||||||||||||
| Ann Arbor stage | ||||||||||||||||||
| I, II | 139 | 81.0 | 3.05 | .0001 | .0001 | 82.8 | 2.87 | .0001 | .0001 | |||||||||
| III, IV | 175 | 57.3 | (1.86-4.99) | 59.3 | (1.70-4.83) | |||||||||||||
| Extranodal sites | ||||||||||||||||||
| 0-1 | 280 | 72.1 | 3.74 | .0001 | .0001 | 72.6 | 2.92 | .0001 | .0002 | |||||||||
| > 1 | 34 | 35.8 | (2.28-6.12) | 48.3 | (1.63-5.22) | |||||||||||||
| B symptoms | ||||||||||||||||||
| Absent | 231 | 74.2 | 2.25 | .0002 | .0001 | 73.4 | 1.83 | .0072 | .0120 | |||||||||
| Present | 83 | 51.1 | (1.47-3.46) | 61.5 | (1.13-2.94) | |||||||||||||
| Bulky disease | ||||||||||||||||||
| Absent | 266 | 70.3 | 1.30 | .5777 | .3522 | 72.0 | 1.41 | .5623 | .2404 | |||||||||
| Present | 46 | 56.5 | (0.74-2.26) | 56.8 | (0.79-2.52) | |||||||||||||
| Age at diagnosis (yr) | ||||||||||||||||||
| < 60 | 124 | 83.5 | 3.18 | .0001 | .0001 | 83.0 | 2.46 | .0008 | .0006 | |||||||||
| ≥ 60 | 190 | 57.9 | (1.87-5.40) | 61.2 | (1.44-4.17) | |||||||||||||
| Sex | ||||||||||||||||||
| Male | 164 | 69.2 | 1.06 | .7366 | .7913 | 69.6 | 1.00 | .9428 | .9940 | |||||||||
| Female | 150 | 63.7 | (0.70-1.61) | 71.5 | (0.64-1.58) | |||||||||||||
| nm23-H1 level (ng/mL) | ||||||||||||||||||
| Control + 2SD ≤ 12.01 | 127 | 83.6 | 3.87 | .0001 | .0001 | 79.5 | 2.72 | .0001 | .0001 | |||||||||
| Control + 2SD > 12.01 | 187 | 58.7 | (2.24-6.68) | 64.8 | (1.60-4.63) | |||||||||||||
| Median ≤ 17.00 | 158 | 83.2 | 4.33 | .0001 | .0001 | 80.4 | 3.32 | .0001 | .0001 | |||||||||
| Median > 17.00 | 156 | 53.9 | (2.62-7.16) | 60.3 | (2.00-5.49) | |||||||||||||
| point ≤ 32.50 | 209 | 81.6 | 5.22 | .0001 | .0001 | 79.5 | 4.11 | .0001 | .0001 | |||||||||
| point > 32.50 | 105 | 42.0 | (3.35-8.13) | 50.8 | (2.59-6.52) | |||||||||||||
| ¾ point ≤ 45.00 | 236 | 81.0 | 7.02 | .0001 | .0001 | 79.7 | 6.06 | .0001 | .0001 | |||||||||
| ¾ point > 45.00 | 78 | 53.9 | (4.55-10.83) | 37.7 | (3.83-9.60) | |||||||||||||
| ≤ 80.00 | 272 | 77.9 | 12.12 | .0001 | .0001 | 77.8 | 14.34 | .0001 | .0001 | |||||||||
| > 80.00 | 42 | 5.5 | (7.73-18.99) | 7.9 | (8.73-23.58) | |||||||||||||
| sIL-2 receptor level (U/mL) ≤ 1000 | 137 | 86.7 | 4.45 | .0001 | .0001 | 85.4 | 3.34 | .0001 | .0001 | |||||||||
| > 1000 | 177 | 53.4 | (2.58-7.66) | 57.5 | (1.96) | |||||||||||||
| sCD44 level (ng/mL) | ||||||||||||||||||
| Median ≤ 464.0 | 111 | 77.4 | 1.82 | .0248 | .0247 | 77.4 | 1.68 | .0557 | .0688 | |||||||||
| Median > 464.0 | 110 | 58.8 | (1.07-3.09) | 63.3 | (0.98-2.89) | |||||||||||||
| Control + 2SD ≤ 598.8 | 141 | 76.3 | 1.86 | .0291 | .0174 | 74.0 | 1.68 | .0401 | .0528 | |||||||||
| Control + 2SD > 598.8 | 80 | 53.6 | (1.11-3.11) | 63.5 | (0.99-2.66) | |||||||||||||
| ≤ 500 | 120 | 78.3 | 2.03 | .0093 | .0071 | 78.3 | 1.89 | .0243 | .0177 | |||||||||
| > 500 | 101 | 55.8 | (1.20-3.43) | 60.8 | (1.11-3.23) | |||||||||||||
CI indicates confidence interval; PFS, progression-free survival; L, low risk; L-I, low-intermediate risk; H-I, high-intermediate risk; H, high risk; WHO, World Health Organization.